焦虑症γ-氨基丁酸受体机制与药物干预研究进展
Progress of the research in GABA receptors and anxiety disorder:mechanism and pharmaceutical intervention
查看参考文献29篇
|
文摘
|
焦虑症是一种常见的精神类疾病,随着社会压力的日益加大,发病率逐渐升高.以往研究证实,焦虑症与γ-氨基丁酸受体有关,现阶段又发现γ-氨基丁酸受体的多个亚型参与了焦虑症的病理生理过程.该文综述了γ-氨基丁酸受体不同亚型在焦虑症发病机制中所起作用及不同机制下药物干预的研究进展 |
|
其他语种文摘
|
Anxiety disorder is a common mental illness. With the growing social pressure, incidence of this disease has been rising gradually. Early studies have proved that GABA receptors play an important role in the progress of anxiety disorders. At present, multiple subtypes of GABA receptors have been discovered which involved in the pathogenesis and treatment of anxiety disorder. The aim of this paper is to review the recent progress of different subtypes of GABA receptors and pharmaceutical intervention via different mechanisms related to anxiety disorder |
|
来源
|
中国药理学通报
,2010,26(9):1135-1138 【核心库】
|
|
关键词
|
焦虑症
;
γ-氨基丁酸受体
;
苯二氮艹卓结合位点
;
神经类固醇结合位点
;
机制
;
药物干预
|
|
地址
|
1.
浙江中医药大学, 浙江, 杭州, 310053
2.
中国科学院心理研究所, 中国科学院心理健康重点实验室, 北京, 100101
3.
北京中医药大学, 北京, 100029
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1001-1978 |
|
学科
|
医药、卫生;基础医学;神经病学与精神病学 |
|
基金
|
国家“十一五”重大科技专项
|
|
文献收藏号
|
CSCD:4047617
|
参考文献 共
29
共2页
|
|
1.
Czobor P. A multicenter, placebo-controlled, double-blind randomized study of efficacy, and safety of ocinaplon(DOV 273,547)in generalized anxiety disorder.
CNS Neurosci Ther,2010,16(2):63-75
|
CSCD被引
1
次
|
|
|
|
|
2.
Olsen R W. GABA A receptors: Subtypes provide diversity of function and pharmacology.
Neuropharmacology,2009,56(1):141-148
|
CSCD被引
10
次
|
|
|
|
|
3.
Low K. Molecular and neuronal substrate for the selective attenuation of anxiety.
Science,2000,290(5489):131-134
|
CSCD被引
6
次
|
|
|
|
|
4.
Atack J R. TPA023,an agonist selective forα2-andα3-containing GABAA receptors,is a nonsedating anxiolytic in rodents and primates.
J Pharm Exp Ther,2006,316(1):410-422
|
CSCD被引
2
次
|
|
|
|
|
5.
Nehrenberg D L. An anxiety-like phenotype in mice selectively bred for aggression.
Behav Brain Res,2009,201(1):179-191
|
CSCD被引
1
次
|
|
|
|
|
6.
Mohler H. Role of GABA A receptors in cognition.
Biochem Soc Trans,2009,37(Pt 6):1328-1333
|
CSCD被引
2
次
|
|
|
|
|
7.
Taliani S. Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the gamma-aminobutyric acid-A (GABA A)alpha2 benzodiazepine receptor.
J Med Chem,2009,52(12):3723-3734
|
CSCD被引
1
次
|
|
|
|
|
8.
Mirza N R. NS11394[3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile],a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy.
J Pharmacol Exp Ther,2008,327(3):954-968
|
CSCD被引
1
次
|
|
|
|
|
9.
Atack J. MRK-409(MK-0343),a GABAA receptor subtype-selective partial agonist,is a non-sedating anxiolytic in preclinical species but causes sedation in humans.
J Psychopharmacol,in press
|
CSCD被引
2
次
|
|
|
|
|
10.
Atack J. Preclinical and clinical pharmacology of TPA023B,a GABA A receptorα2/α3 subtype-selective partial agonis.
J Psychopharmacol,in press
|
CSCD被引
2
次
|
|
|
|
|
11.
Benke D. GABA(A)receptors as in vivo substrate for the anxiolytic action of valerenic acid,a major constituent of valerian root extracts.
Neuropharmacology,2009,56(1):174-181
|
CSCD被引
1
次
|
|
|
|
|
12.
Gee K W. Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia.
J Pharmacol Exp Ther,2010,332(3):1040-1053
|
CSCD被引
1
次
|
|
|
|
|
13.
Rudolph U. GABA-based therapeutic approaches: GABAA receptor subtype functions.
Curr Opin Pharmacol,2006,6(1):18-23
|
CSCD被引
10
次
|
|
|
|
|
14.
Licata S C. Abuse and dependence liability of benzodiazepine-type drugs GABAA receptor modulation and beyond.
Pharmacol Biochem Behav,2008,90(1):74-89
|
CSCD被引
6
次
|
|
|
|
|
15.
Scott-Stevens P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
Biopharm Drug Dispos,2005,26(1):13-20
|
CSCD被引
2
次
|
|
|
|
|
16.
de Haas S L. Pharmacodynamic and pharmacokinetic effects of MK-0343,a GABA(A)alpha2, 3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
J Psychopharmacol,2008,22(1):24-32
|
CSCD被引
2
次
|
|
|
|
|
17.
Ren L H. GABA A receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone.
Biochem Pharmacol,2010,79(9):1337-1344
|
CSCD被引
2
次
|
|
|
|
|
18.
Hosie A M. Conserved site for neurosteroid modulation of GABAA receptors.
Neuropharmacology,2009,56(1):149-154
|
CSCD被引
1
次
|
|
|
|
|
19.
杨红菊. 吲哚衍生物I20的抗焦虑作用及机制研究.
中国药理学通报,2002,18(4):422-425
|
CSCD被引
5
次
|
|
|
|
|
20.
Kita A. Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216,a selective TSPO ligand.
Prog Neuropsychopharmacol Biol Psychiatry,2009,33(6):1040-1045
|
CSCD被引
4
次
|
|
|
|
|
了解气象卫星更多信息，请访问